The size of the Global Hemophilia Management Market was worth USD 5.35 billion in 2020 and is estimated to be growing at a CAGR of 1.62% to reach USD 5.8 billion by 2025. Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting. Hemophilia usually occurs in males; it is estimated that about 1 in 5000 males that are born each year contain hemophilia.
Hemophilia is categorized into three levels depending on its severity as severe, moderate, and mild. About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people. It is estimated that about 75% of the hemophilia patients do not receive adequate treatment.
MARKET DRIVERS
The growing prevalence of the disease and increasing usage of the recombinant product is expected to drive the market growth. Technological advancements and advancements in the novel are coagulating factors and are also fuelling the growth of the global Hemophilia Management market. Rising investments in Research and developments for hemophilia products are even driving market growth.
The increase in the number of hemophilic patients is driving worldwide demand for recombination. The rise in consumer disposable income, healthcare spending, advances in medical care, and the increase of new trends like medical tourism are factors promoting the developments in the global hemophilia management market. There should be an increase in competitiveness in driving the global demand for this market. To meet the changing needs of the business and also to solve the existing challenges, the above factor drives away the growth of the market. Introduction to new drug launches is one of the factors driving the global hemophilia management Market.
Gene therapy advancements and the approach of approval of drugs for the treatment of hemophilia offer immense opportunities for the growth of the hemophilia management market. Production rise recombinant of factor concentrates has provided the growth opportunity to treat hemophilia and overcome the availability of plasma-derived concentrates. Research and analysis focus on upcoming market trends and offer insights to help business market opportunities and develop an effective strategy to optimize their market positions.
MARKET RESTRAINTS
The major restraint for the growth of the global hemophilia management market is the high cost of treatment. Awareness of this disease in the population and lack of medicine availability is also the major restraining factor in the market. Plasma treatment products have adverse side effects, which are expected to restrain industry growth during the forecast period. The high cost of products is unaffordable to the lower and middle-income families, which results in a slow expansion of the Global hemophilia management market.
There are multiple challenges in the global hemophilia management market, such as the high quality of funding and implementation, evidence-based hemophilia care, and guideline-driven. An ongoing challenge to long-term medical conditions is sticking fast to treatment recommendations ad following up them. The development of alloantibodies against the infused factor concentrates on hemophilia treatment is also one of the challenging aspects.
IMPACT OF COVID-19 ON THE GLOBAL HEMOPHILIA MANAGEMENT MARKET
COVID-19 has impacted the market in a lot of ways. The lockdown has resulted in more people sitting inside their homes. Thus, the patients who have mild Haemophilia could not take treatment at home, thus increasing the disease's severity. The supply chain was disrupted during the lockdown, and therefore people were not able to self-medicate properly, thus negatively impacting the industry. The shift in research to find the cure of the virus has further delayed any research and development of this disease's medication.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type, Drug and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
In this research report, the global hemophilia management market has been segmented and sub-segmented based on the type, drug, and region.
Hemophilia Management Market - By Type:
Based on type, Hemophilia A segment is projected to have the highest growth rate driven by many patients suffering from hemophilia A.
Haemophilia A had the largest share in the market due to more cases of Haemophilia A patients. Haemophilia A is caused due to deficiency of the factor VIII. Haemophilia A symptom is bleeding in joints and swelling in joints. Other symptoms are unexplained bleeding and blood in urine or stool. Haemophilia A occurs with an incidence of 1 in 500 to 10 000 males. The rise in research companies trying to find a cure will drive the growth of the management market.
Haemophilia B cases are second in number and are expected to increase in the future. It is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. The prevalence of hemophilia B is 1 in 100000 males, and around 44% of them suffering from it. The symptoms are bleeding from joints, bleeding from the nose, bruising, blood from urine or stool, etc.
Hemophilia Management Market - By Drug:
The most common drug used for treatment is octocogalfa. It is used to decrease the deficiency of factor VIII. The more cases of Haemophilia A have driven this market and are expected to grow at a reasonable rate in the future.
Nonacog alfa is second in terms of market share and is expected to grow positively in the future. It is a purified protein produced by recombinant DNA technology for use in hemophilia B therapy. The rise in cases of Haemophilia B will drive the growth of this market.
Desmopressin has the third-largest market share, among others, and is expected to grow at a reasonable rate. It is used in mild cases of Haemophilia A, and thus rise in hemophilia A cases will drive the market growth. This medication helps to control increased thirst and too much urination Due to Haemophilia and helps prevent dehydration.
Hemophilia Management Market - By Region:
Geographically, North America is the largest market for hemophilia management, accounting for approximately XX% due to high government support and the increasing number of patients who have hemophilia. Europe is the second-largest market for hemophilia management. Asia-Pacific region is estimated to be the fastest-growing region due to its high population base and increased healthcare expenditure. Latin America region provides a lucrative opportunity for growth attributed to local government support and the increasing focus of global players towards emerging economies.
Key market participants playing a dominating role in the global hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, Swedish Orphan Biovitrum AB.
RECENT MARKET HAPPENINGS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
